Torrent Pharmaceuticals has scheduled a teleconference with investors and analysts for October 23, 2026, at 5:30 pm IST. The session will focus on the company's financial performance for the quarter and half year ended September 30, 2026.

Conference call details

The company will discuss its Q2FY27 results during the scheduled interaction. Participants can join via universal dial-in numbers or international toll-free lines provided in the official notice.

Dial-in information

Investors and analysts can access the conference call using the following contact details:

• Universal dial-in: +91 22 6280 1439, +91 22 7115 8803
• India National Toll Free: 1 800 120 1221
• International Toll Free: Available for Argentina, Australia, Belgium, Canada, China, France, Germany, Hong Kong, Italy, Japan, Netherlands, Poland, Singapore, South Korea, Sweden, Thailand, UK, and USA.

Registration is required via the Diamond Pass link provided by the company. The notice was signed by Chintan M. Trivedi, Company Secretary, on October 9, 2026.

Torrent Pharmaceuticals has increased its investment in Torrent Urja 27 Private Limited to ₹11.88 crore to support a captive hybrid power project in Gujarat. The amendment, executed on September 28, 2026, raises the company's equity subscription from ₹7.92 crore to accommodate an expansion in project capacity.

The transaction involves subscribing to 26% of the equity shares of Torrent Urja, a special purpose vehicle formed for setting up the solar and wind energy project. The move aims to enhance the share of renewable power sources in the company's operations and ensure compliance with regulatory requirements for captive users under Indian electricity laws.

Transaction details

The revised investment reflects an increase in the project capacity of the target entity. The consideration is entirely in cash, structured through the purchase of Class A Equity Shares with a face value of ₹10 each.

Strategic rationale and structure

Torrent Urja is currently a wholly owned subsidiary of Torrent Green Energy Private Limited and serves as an associate company of Torrent Pharmaceuticals. The transaction is classified as a related party deal, conducted on an arm's length basis. The entity was incorporated in August 2024 and is yet to commence business operations, reporting nil turnover as on March 31, 2026.

The primary objective is to secure a reliable source of renewable energy for the pharmaceutical major's manufacturing facilities. By increasing its stake, Torrent Pharmaceuticals aligns its capital allocation with its sustainability goals while adhering to the legal frameworks governing captive power consumption in India.